This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Hims & Hers Health Class Action
Business class action

Hims & Hers Health Class Action

Analysis based on 8 articles · First reported Jul 02, 2025 · Last updated Aug 07, 2025

Sentiment
-60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Hims & Hers Health for deceptive practices regarding Semaglutide® knockoffs is likely to negatively impact Hims & Hers Health's stock price and reputation. There is also a substantial risk of termination of its collaboration with Novo Nordisk, which could further harm Hims & Hers Health's market position.

Healthcare Pharmaceuticals
Event Summary

The Gross Law Firm has issued multiple notices to shareholders of Hims & Hers Health, informing them of a pending class action lawsuit. The lawsuit alleges that Hims & Hers Health engaged in the deceptive promotion and selling of illegitimate, 'knockoff' versions of Semaglutide®, which posed risks to patient safety. These actions allegedly led to materially false and misleading statements by Hims & Hers Health regarding its business operations and prospects. The complaint also highlights a substantial risk that Hims & Hers Health's collaboration with Novo Nordisk could be terminated as a result of these alleged practices. The class period for affected shareholders is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025.

Entities Involved
stock
Hims & Hers Health
Hims & Hers Health is facing a class action lawsuit for allegedly making false and misleading statements regarding its business practices, specifically the deceptive promotion and selling of 'knockoff' versions of Semaglutide®, which could lead to the termination of its collaboration with Novo Nordisk.
Importance 100.0 Sentiment -70.0
stock
Novo Nordisk
Importance 0.0 Sentiment 0.0
Relationships
Hims & Hers Health competitor ↔ Novo Nordisk Hims & Hers Health is facing legal threats from Novo Nordisk after their brief distribution partnership was terminated o
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.